Aug 8 (Reuters) - Novavax on Tuesday posted an unexpected second-quarter profit on earlier-than-expected revenue from its COVID-19 vaccine, but still trimmed its full-year forecast for sales of the shot.
Revenue was $424 million in the quarter, up from $186 million a year ago, helped by a $100 million payment that Canada made in order to cancel doses that it had ordered for 2022.
Analysts had expected revenue of $240 million, according to Refinitiv IBES data.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments